Genetic approaches in model organisms provide a powerful means by which to examine the biological basis of human diseases as well as the physiological processes that are affected by them. Although not without its drawbacks, the mouse has become the mammalian species of choice in studying the molecular basis of disease. Targeted mutagenesis approaches in the mouse have led to dramatic increases in our understanding of human disease processes. As a complement to these gene-driven studies, three developments have led to the reassessment of a phenotype-driven approach in the mouse -the accumulation of information that has emerged from human and mouse genome sequencing projects, the use of high-efficiency point mutagens such as N-ethyl-N-nitrosourea (ENU) and the application of systematic hierarchical screening protocols for the mouse. In this paper, progress with existing phenotypic screening programmes is discussed and opportunities for the development of new mouse disease models are presented.
INTRODUCTION
Studies of human genetic disease are often complicated by difficulties in access to tissues or by genetic heterogeneity in families inheriting these disorders. The use of model organisms that are amenable to genetic manipulation provides an easier access to studying these disorders. For this purpose, the application and incorporation of genetic screens have contributed substantially to our understanding of the biological basis of human physiological and diseased states. For example, large-scale screens in Drosophila have led to breakthrough developments in our understanding of embryonic patterning and organogenesis 1 and in the molecular basis of behaviour and central nervous system function. 2, 3 Many of the genes identified in screens for fly mutants have provided entry points into establishing the function of human orthologues. By increasing the complexity and specificity of screening protocols, screens in the worm, Caenorhabditis elegans, and in the zebra fish, Danio rerio, have allowed us to investigate more specific cellular functions such as nerve and muscle function. [4] [5] [6] Although genetic screens in these organisms have undoubtedly had a tremendous impact on the analysis of gene function, limitations arise in the relatively lower complexity of their physiology and in the evolutionary diversification of their genomes when compared with humans.
An ideal model organism in which to study the basis of human inherited disease then would be one which is relatively amenable to genetic manipulation, where comparative analysis with the human genome can be performed and where the physiology of the species is similar in complexity to that of humans. The mouse is a suitable organism for such studies. Many mouse mutations have been established as reliable models of human disease while others have provided insight into complex developmental and physiological pathways in mammals. 7 For example, in the investigation of the molecular basis of epilepsy in humans, the mouse mutants stargazer, tottering and lethargic have furthered our understanding of the mechanism of action of neuronal voltage-gated calcium channels and the phenotypic consequences when these genes are altered. 8 Nevertheless, until recently, phenotypic screens in mice had been relatively modest, often concentrating on easily detectable phenotypes (such as coat colour, growth abnormalities etc.) or limited to a single phenotypic assay. 9 Difficulties encountered in carrying out large-scale phenotypic screens in the mouse have included space and financial constraints. Two issues have altered this viewpointthe use of the supermutagen N-ethyl-Nnitrosourea (ENU) and the marriage of systematic hierarchical screening protocols with sophisticated automated screening technologies.
ENU MUTAGENESIS IN THE MOUSE
ENU is a powerful alkylating agent, which has been found to be highly mutagenic in mouse spermatogonial germ cells. 10 Unlike other mutagens, genetic lesions induced by ENU are primarily point mutations, meaning that observed phenotypes will be a consequence of single gene effects. By assessing mutation rates at a number of visible marker loci, it has been estimated that ENU can induce functional mutations at gene loci at the rate of approximately one per 1,000 genomes. Although this assumption has been upheld in some cases, 11 actual per locus mutation rates can vary from one in 300 genomes screened 12 to almost one in 5,000 genomes screened. 13 This apparent bias in mutation induction could be attributed to a number of factors, as detailed below.
ENU preferentially alkylates AT base pairs
A comparison of 62 sequenced ENUinduced mutations revealed that the chemical primarily causes AT to TA transversions (44 per cent) and AT to GC transitions (38 per cent).
14 The net result of this would be that AT-rich genes are more likely to be mutagenised.
Nevertheless, ENU does not exclusively mutagenise AT base pairs. A recent paper describing a gene-driven approach using ENU found only GC to TA transitions (60 per cent) and AT to GC transitions (40 per cent) in a total of 9.48 megabases of DNA screened. 15 
Mouse strain differences
The mutagenic and cytotoxic effects of ENU vary depending on the dosage regimen and strain of animal used. 10, 16 A titration of dose is required when considering a particular strain for mutagenesis. Generally, it is recommended that a strain be chosen which is susceptible to the mutagenic effects and not to the cytotoxic effects of ENU. Some strains are also preferentially selected as they may be susceptible or resistant to a particular trait being studied, eg a susceptibility to late-onset hearing loss. 17 It is also perhaps worth noting that the mutation rate at particular loci may be dependent on the strain mutagenised. 18 In one report, the phenotype being studied was circling behaviour, an indicator of a vestibular deficit in mice. In cases where BALB/c mice were mutagenised, the majority of circling phenotypes map to a locus on proximal mouse chromosome 4. Circling phenotypes that map to this locus are not seen when C3H mice are mutagenised. 19 Inappropriate assays are used to assess mutant phenotypes Our knowledge of gene function is limited and often biased by particular scientific assumptions. This has become evident in the analysis of mutant lines that have arisen from two large-scale phenotype-driven mutagenesis screens 19, 20 where there were no prior assumptions of gene function. Both of these large-scale screens had incorporated tests for auditory and vestibular function among their screening repertoire and both identified mutant lines with deafness resulting from patterning deficits in the developing inner ear. The mutant gene in each case was identified as Jagged1, for the first time implicating this gene in the signalling processes that pattern the inner ear neuroepithelium. 21, 22 Considering this, the use of systematic hierarchical screens on populations of mutagenised mice will be essential not only to assess the function of previously uncharacterised genes but also to reassess the function of genes that might be considered to be well characterised.
SCREENING FOR RELEVANT PHENOTYPES
Published reports detailing the results of genome-wide ENU mutagenesis screens 19, 20 have provided support for the use of integrative screening protocols. In the same populations of mutagenised mice, founder animals exhibiting neurological, behavioural, sensory, skeletal, biochemical, immunological or haematological anomalies could be identified. In total, approximately two per cent of animals screened exhibited an identifiable phenotype. In the majority of cases, anomalies were identified only in one measured system; however, the use of integrated approaches also allowed for the identification of founder animals with complex phenotypic profiles (eg some mice with skin or hair pigmentation defects also presented with a neurological or behavioural phenotype).
As a result of the success of these earlier screens, various research centres worldwide have incorporated high throughput biological screening of ENUmutagenised mice into functional genomics research programmes. The ultimate goal of this ambitious exercise would be to create banks of mouse lines containing mutations at every gene locus. Although it could be argued that there is an overlapping duplication of effort in these centres, the diversity of screens and approaches used ensures that this will not be the case. Perhaps the most comprehensive of these screening projects has been established to identify dominant and recessive neurological and behavioural mutant lines on a genomewide basis. 23 In addition to large mutagenesis centres, smaller research groups are carrying out more specialised and complex screens. Table 1 lists some of the screens currently underway with reference to some of the published reports and Table 2 provides information on web databases. Phenotypes screened range from development and organogenesis to late-onset anomalies and include genomewide as well as region-specific screens. Reviews on these topics have been previously published. [47] [48] [49] [50] A common feature of many of the large-scale mutagenesis projects is that mutant phenotypes are published online as soon as founder mice are identified. A certain percentage of these are also inheritance tested and this information is also published. One of the features of the screens is that mutant lines are available to any interested researcher. The success of these projects will depend on global access to these resources. In order to instigate this, the following should be considered.
Classification and characterisation of mutant phenotype
Many of the large mutagenesis centres give brief phenotypic descriptions of mice identified in screens and can inform interested investigators by e-mail when particular phenotypes have been identified. Generally, this involves registering an interest in a particular class of phenotypes at any of the various mutagenesis websites (some of these are detailed in Table 2 ). In order that phenotypic data may be successfully searched for and analysed, a hierarchical group of search terms and a complete vocabulary of phenotypic descriptions is currently being developed and will be appropriated by some of the mutagenesis centres. More information on the use of these search terms can be found at the Jackson Laboratory Mouse Genome Informatics site. 51 
Ease of movement of mouse lines
Many of the mutant phenotypes identified in screens will not be maintained as live colonies but will be archived as frozen embryos or sperm (and, to a lesser extent, frozen oocytes). Easier access to these archives will require the development of in-house techniques such as embryo re-derivation, artificial insemination and in vitro fertilisation (IVF).
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Standardisation of phenotypic tests
Standardisation of phenotype ontology must be accompanied by standardisation of phenotypic assays and methods of analysis.
MAPPING AND ANALYSIS OF MUTANT LINES
One of the drawbacks of using chemical mutagenesis is that, having identified an aberrant phenotype, it still requires considerable effort to identify the underlying gene. Again, a systematic stepwise approach has been shown to be successful. A flow chart representing an example of this approach is indicated in Figure 1 . One of the first stages in Mutant phenotypes are published online
Register by e-mail for phenotypes of interest 53 sufficient backcross animals can be generated for this purpose. 20 A rapid mapping strategy making use of fluorescent microsatellite primer pairs, pooling of DNA samples based on phenotypic classification and pooling of amplicons based on allele size and fluorescence has been used to define a genomic segment containing the ENUinduced mutation. 39 In this case, this lowresolution map position, along with some preliminary phenotypic data, was enough to identify Pmp22 as a candidate gene and to propose two allelic mutations as models for the study of inherited peripheral neuropathies such as Charcot-MarieTooth type 1A, Dejerine Sottas syndrome and hereditary neuropathy with liability to pressure palsies. Herron et al. 26 used another rapid mapping strategy, termed interval haplotype analysis, to identify recessive mutations induced by ENU. The screen was for anomalies of organogenesis at embryonic day 18.5 and, using DNA from eight affected mice and only two markers per chromosome (three in the case of chromosomes 1 and 2), 14 recessive mutant loci were mapped and confirmed. In two cases, comparison of the embryonic phenotype of the ENUmutants with published targeted mutants led to the identification of the affected genes. One line had a rib and muscle phenotype reminiscent of that seen in patients with congenital muscular dystrophies and in mice targeted for the ryanodine receptor (Ryr1). Allelism was confirmed by complementation testing. A second showed severe oedema, with an enlarged pancreas and polycystic kidneys similar to those seen in targeted mutations for the genes causing human polycystic kidney disease (Pkd1 and Pkd2). Sequencing confirmed a missense mutation in Pkd1. Similar candidate-gene approaches have been used to identify mutations in a mouse line with progressive hearing loss 32 and in several lines with dominant cataracts. [54] [55] [56] By the same standards, ENU is equally likely to induce mutations in previously uncharacterised genes or in regions of genes that may not be detected easily. Although the effort to clone these classes of mutation will be far greater, the rewards will also be greater as they will reflect more accurately the broad spectrum of human disease-causing mutations and ultimately add to the understanding of gene function. It is now apparent that even translationally silent exonic point mutations 57 or simple deletions within introns 58 can result in splicing mutations and contribute to disease phenotypes in humans. According to a review published in 1999, mutations induced by ENU in the mouse can vary, Potential to reflect a broad spectrum of human disease-causing mutations 14 So far, recent mutagenesis efforts have added to the two former categories but not the latter, perhaps as mutations resulting in splicing anomalies as well as other non-coding sequence mutations will be more difficult to detect. As more mutant lines are characterised, it is expected that many mutations such as these will be identified. Considering the batteries of novel phenotypic screens employed and the varied approaches to mutagenesis, it is also expected that many mutations at novel gene loci will be identified. This is true even where newly characterised mutant lines appear to phenocopy established mouse lines. Herron et al. 26 found that a mutation affecting the axial skeleton which is similar to that described for the pudgy mutation (delta-like 3, Dll3) maps to a genetic locus that excludes any delta-like family member as a candidate. Similarly, the authors have found deafness, pigmentation, ataxia and other mutants that map to gene loci that had not previously been associated with such phenotypes. 20, 59 In screens for immune system function, Nelms and Goodnow 43 suggest that the majority of recessive lines identified also fall within this category.
DETECTION OF MUTATIONS
As more mutant lines are identified and characterised, demands on mapping and genotyping resources will increase. Even currently, it would appear that the ratelimiting step in the detection of mutations is in mapping and genotyping. Although the speed at which genotyping can be carried out is a factor, the lack of an appropriately dense set of polymorphic markers is hindering the rate at which mutations can be detected. For example, using the BALB/c and C3H inbred strains for mapping ENU-induced mutations, available sets of polymorphic markers will provide a map position with an average resolution of only about 1-2 centimorgans. Moreover, the authors' experience has shown that several genomic regions -eg almost all of mouse chromosome 9 -are even more sparsely distributed with markers polymorphic for these two strains. Currently, marker-poor regions are being successfully scanned for additional polymorphisms, although progress in this field is quite slow. Detection of mouse strain single nucleotide polymorphism sets and the development of high throughput genotyping assays will undoubtedly accelerate the transition from phenotype to gene.
ALLELIC SERIES AND GENE FUNCTION
One of the benefits of conducting largescale mutagenesis screens is that multiple mutant phenotypes will be generated for each gene locus. In several screens for eye defects, 11, 30 allelic series at the Pax6 locus have been identified with differing results. Dominant mutations at the Pax6 locus result in an easily identifiable small eye phenotype, sometimes with additional anterior segment defects. Evidence for human ocular disorders with an underlying PAX6 mutation, such as aniridia and Peters' anomaly, 60 make this an interesting candidate for gene function studies. Nine independent Pax6 mutations were identified in a large dominant screen for eye morphological defects. 61 Of these, seven were nonsense, resulting in premature termination of translation and expressing a phenotype characteristic of null alleles; however, two alleles were due to missense mutations and expressed a phenotype suggesting a less severe hypomorphic allele. Thaung et al. 11 identified four novel Pax6 mutant alleles in a total of 6,500 mice screened (giving an estimated per locus mutation rate for dominant mutations of 0:62 3 10 À3 ). Three of the four alleles were due to missense mutations and one introduced a premature stop codon. It was not confirmed whether these alleles were null or hypomorphic in nature, although some showed identical Many mutants map to novel gene loci although they phenocopy existing mutant lines Multiple mutant phenotypes can be generated at each gene locus Identification of additional strain polymorphisms will facilitate positional cloning mutations and/or protein structural changes to those found in human patients.
ENU mutagenesis can be adapted successfully to identify additional alleles at any gene locus for which mutants are already available (either targeted or naturally occurring mutations). In many cases, the phenotypic effects of targeted null mutations may be too severe to carry out functional studies in adult mice. As evidenced below, the identification of allelic series at particular gene loci may provide more suitable mouse models in the study of human disorders. Cordes and Barsch 12 used this approach to screen for additional alleles of the kreisler (Krml) mutant. In 600 mice, 50 per cent of which carried one copy of the kr mutation, an additional allele was identified. Thaung et al.
11 screened for eye defects in a population of mice that were heterozygous for the Pde6b rd1 mutation, a recessive mutation resulting in retinal degeneration and carried by the C3H inbred strain. Mutations in the human gene are responsible for the largest proportion of identified recessive retinitis pigmentosa mutations. 62 Unfortunately, the Pde6b rd1 mutation in mice causes a fast retinal degeneration with 98 per cent of the rod photoreceptor cells lost by postnatal day 17, 63 making it unsuitable as a model for investigating human disease mechanisms. Seven additional Pde6b alleles were identified in this screen, three of which cause a slower onset of degeneration than that of Pde6b rd1 homozygotes. The suitability of these mutant alleles in the study of human retinal degeneration diseases has yet to be tested.
THE GENOTYPE-DRIVEN APPROACH
It is clear from the success of phenotype screening of ENU mutagenised mice that the mutagenesis of the mouse genome is highly efficient and reproducible. This raises the possibility that instead of screening for phenotypes one could take a gene of interest and search for mutations specifically in that gene using conventional mutation detection technologies (see Figure 2) . In order to do this, a DNA sample would be required from each mouse. Since technologies exist for the archiving of mice as frozen sperm, ovaries or embryos, it would be efficient to parallel these DNA samples with frozen germ material so that an archive could be constructed and screened systematically without the need to generate new mice. A logical step from this concept is the idea that mutagenesis could be carried out in embryonic stem cells where doses of mutagen can be more easily adjusted and optimised without animal welfare and viability considerations. Those stem cells could again be paralleled as DNA and frozen cell archives for screening, and then mice generated for full phenotyping using embryo chimaera technologies.
Sperm and DNA archives
Coghill et al. 15 have shown that this approach is effective. They have constructed an archive of over 2,000 DNAs paralleled by sperm samples and have screened this with five candidate genes, and recovered five alleles of which three were functional and one was recovered as a living mouse line with a phenotype. This yields a functional mutation rate of about one in 3.16 megabases and is a little lower than that predicted from the mutation rate at the Pde6b locus in the same mutagenesis experiments. The true mutation rate will not become apparent until many more genes have been screened. Coghill et al. 15 predict that, in order to have a .90 per cent chance of finding three or more alleles, an archive of over 5,000 mice would be required. The authors' group is constructing such an archive.
Embryonic stem cell approaches
Chen et al. 64 and Munroe et al. 65 have shown that mouse embryonic stem (ES) cells can be mutagenised efficiently in cell culture and then used to generate chimaeras capable of germ-line transmission. There are several possible Screening for allelic series using targeted mutant lines Identification of less severe phenotypes at gene loci may benefit human disease studies PCR-based screens for mutations in candidate genes advantages to this approach. First, different mutagens (ENU, EMS, ICR191 etc.) can be used, yielding different spectra of mutations and leading to more comprehensive coverage and informativeness of allelic series. Second, doses can be manipulated without immediate animal welfare considerations and combinations of agents used, allowing manipulation of the burden of mutations (eg increasing the burden or decreasing it in order to avoid potential confounding effects of multiple mutations). Third, large-scale mutation screens can be carried out using ES cell-derived material without the need to breed and house mice. Finally, some phenotyping is possible directly on ES cells or following differentiation in vitro -eg by expression profiling and proteomics. This approach has the potential to be highly effective once the logistical methods are developed for screening; an ES cell archive would be important in this respect. If it is possible to increase the mutation burden, a smaller archive could be used or an archive of the scale suggested above but with more alleles recovered.
Mutation detection technologies
Mutation detection within the DNA archive can be carried out rapidly using a number of methods including high throughput sequencing. There are many established technologies including direct sequencing and fluorescent singlestranded conformational polymorphism 
APPROACHES TO DISEASES WITH A COMPLEX GENETIC BASIS
Diseases where susceptibility is determined by the inheritance of alleles at many genes that either contribute a cumulative additive effect or directly synergise in some way present particular difficulties for mapping and cloning, especially in heterogenous human populations. How might a technique such as mutagenesis be applied to a disease that has complex genetic control? Since the models generated are essentially monogenic, one could approach a complex disease with the intention of generating a series of monogenic disorders. These would be the result of more severe alleles than are found in normal human populations or by the detection of milder alleles in sensitive assays that define sub-disease phenotypes that can be measured accurately and reproducibly in model systems. The discovery of such genes may lead to the identification of new pathways for analysis in human disease. The authors' interest is in type 2 diabetes, and a number of ENU models that exhibit impaired glucose tolerance and diabetes in an intraperitoneal glucose tolerance test have been identified. These models segregate as dominant monogenic traits. A supplementary approach is to sensitise an ENU mutagenesis screen by the use of other mutations (see Nelms and Goodnow 43 ). The authors have been carrying out mutagenesis on an insulinresistant background that does not cause overt diabetes that has allowed the recovery of some new inherited models where the phenotype is enhanced or modified by the presence of a heterozygous insulin receptor null mutation. Given the wide range of knockout mutations available, and a knowledge of the physiology of a system, this approach could be applied to many disease areas. The application of this approach to the study of complex human disease traits provides just one of many exciting opportunities for the development of ENU-based gene function studies.
